

AddriÃ¡n Llerena

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3641737/publications.pdf>

Version: 2024-02-01

161
papers

4,556
citations

94433

37
h-index

133252

59
g-index

172
all docs

172
docs citations

172
times ranked

3800
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacogenetics research in Brazil: a systematic review. <i>Pharmacogenomics</i> , 2022, 23, 263-275.	1.3	0
2	Population genetics of <i>PDE4B</i> (phosphodiesterase-4B) in neglected Native Americans: Implications for cancer pharmacogenetics. <i>Clinical and Translational Science</i> , 2022, , .	3.1	4
3	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	3.3	107
4	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C9</i> and <i>HLA-B</i> Genotypes and Phenytoin Dosing: 2020 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 302-309.	4.7	102
5	Relationships between <i>CYP1A2</i> , <i>CYP2C9</i> , <i>CYP2C19</i> , <i>CYP2D6</i> and <i>CYP3A4</i> metabolic phenotypes and genotypes in a Nicaraguan Mestizo population. <i>Pharmacogenomics Journal</i> , 2021, 21, 140-151.	2.0	12
6	The need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. What's next? An urgent clinical unmet need for patients. <i>Drug Metabolism and Personalized Therapy</i> , 2021, .	0.6	1
7	Relevance of <i>NR112</i> variants on carbamazepine therapy in Mexican Mestizos with epilepsy at a tertiary-care hospital. <i>Pharmacogenomics</i> , 2021, 22, 983-996.	1.3	0
8	Genomic Ancestry, <i>CYP2D6</i> , <i>CYP2C9</i> , and <i>CYP2C19</i> Among Latin Americans. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 257-268.	4.7	27
9	High prevalence of <i>CYP2D6</i> ultrarapid metabolizers in a mestizo Colombian population in relation to Hispanic mestizo populations. <i>Pharmacogenomics</i> , 2020, 21, 1227-1236.	1.3	0
10	Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy. <i>Pharmacogenomics Journal</i> , 2020, 20, 845-856.	2.0	6
11	Clinical implementation of pharmacogenetics and personalized drug prescription based on e-health: the MedeA initiative. <i>Drug Metabolism and Personalized Therapy</i> , 2020, .	0.6	3
12	Current Insights into Interethnic Variability in Testicular Cancers: Population Pharmacogenetics, Clinical Trials, Genetic Basis of Chemotherapy- Induced Toxicities and Molecular Signal Transduction. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 1824-1838.	2.1	4
13	Clinical implementation of pharmacogenetics and personalized drug prescription based on e-health: the MedeA initiative. <i>Drug Metabolism and Drug Interactions</i> , 2020, 35, .	0.3	1
14	The need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. What's next? An urgent clinical unmet need for patients. <i>Drug Metabolism and Drug Interactions</i> , 2020, 35, .	0.3	0
15	Frequency of <i>CYP2C9</i> (*2, *3 and IVS8'109A>T) allelic variants, and their clinical implications, among Mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin. <i>Biomedical Reports</i> , 2019, 10, 283-295.	2.0	4
16	Pharmacogenetics of amfepramone in healthy Mexican subjects reveals potential markers for tailoring pharmacotherapy of obesity: results of a randomised trial. <i>Scientific Reports</i> , 2019, 9, 17833.	3.3	5
17	Genetic structure of pharmacogenetic biomarkers in Brazil inferred from a systematic review and population-based cohorts: a RIBEF/EPIGEN-Brazil initiative. <i>Pharmacogenomics Journal</i> , 2018, 18, 749-759.	2.0	25
18	Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis. <i>Schizophrenia Research</i> , 2018, 193, 188-196.	2.0	50

#	ARTICLE	IF	CITATIONS
19	Interethnic Variability in <i>CYP2D6</i> , <i>CYP2C9</i> , and <i>CYP2C19</i> Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics. <i>OMICS A Journal of Integrative Biology</i> , 2018, 22, 575-588.	2.0	32
20	Effects of Khat (<i>Catha edulis</i>) use on catalytic activities of major drug-metabolizing cytochrome P450 enzymes and implication of pharmacogenetic variations. <i>Scientific Reports</i> , 2018, 8, 12726.	3.3	20
21	Impact of <i>NTRK2</i> , <i>DRD2</i> and <i>ACE</i> polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis. <i>Journal of Psychopharmacology</i> , 2018, 32, 702-710.	4.0	8
22	New perspectives in personalised medicine for ethnicity in cancer: population pharmacogenomics and pharmacometrics. <i>Drug Metabolism and Personalized Therapy</i> , 2018, 33, 61-64.	0.6	9
23	Lessons from Cuba for Global Precision Medicine: <i>CYP2D6</i> Genotype Is Not a Robust Predictor of <i>CYP2D6</i> Ultrarapid Metabolism. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 17-26.	2.0	20
24	Water pipe (Shisha, Hookah, Arghile) Smoking and Secondhand Tobacco Smoke Effects on <i>CYP1A2</i> and <i>CYP2A6</i> Phenotypes as Measured by Caffeine Urine Test. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 177-182.	2.0	2
25	Intuitive pharmacogenetic dosing of risperidone according to <i>CYP2D6</i> phenotype extrapolated from genotype in a cohort of first episode psychosis patients. <i>European Neuropsychopharmacology</i> , 2017, 27, 647-656.	0.7	13
26	Elevated <i>CYP2C19</i> expression is associated with depressive symptoms and hippocampal homeostasis impairment. <i>Molecular Psychiatry</i> , 2017, 22, 1155-1163.	7.9	39
27	What is the future of pharmacogenomics in pain management?. <i>Pharmacogenomics</i> , 2017, 18, 101-103.	1.3	2
28	<i>CYP450</i> Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations—Where to from Here for Global Precision Medicine?. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 509-519.	2.0	30
29	Multiple adverse drug reactions and genetic polymorphism testing. <i>Medicine (United States)</i> , 2017, 96, e8505.	1.0	5
30	Therapeutic Drug Monitoring of Fluoxetine, Norfluoxetine and Paroxetine: A New Tool Based on Microextraction by Packed Sorbent Coupled to Liquid Chromatography. <i>Journal of Analytical Toxicology</i> , 2017, 41, 631-638.	2.8	20
31	Can the CEIBA Cocktail Designed for Human Cytochrome P450 Enzymes be Used in the Rat for Drug Interaction Studies?. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2016, 19, 520.	2.1	7
32	Predictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen. <i>Drug Metabolism and Personalized Therapy</i> , 2016, 31, 83-90.	0.6	11
33	Pharmacogenomics in pain treatment. <i>Drug Metabolism and Personalized Therapy</i> , 2016, 31, 131-142.	0.6	15
34	Pharmacogenetic research activity in Central America and the Caribbean: a systematic review. <i>Pharmacogenomics</i> , 2016, 17, 1707-1724.	1.3	7
35	To Genotype or Phenotype for Personalized Medicine? <i>CYP450</i> Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population. <i>OMICS A Journal of Integrative Biology</i> , 2016, 20, 699-710.	2.0	31
36	Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers. <i>Pharmacogenomics</i> , 2016, 17, 1913-1930.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Genetic variability of <i>CYP2C9*2</i> and <i>CYP2C9*3</i> in seven indigenous groups from Mexico. <i>Pharmacogenomics</i> , 2016, 17, 1881-1889.	1.3	4
38	Pharmacogenetics and ethnicity: relevance for clinical implementation, clinical trials, pharmacovigilance and drug regulation in Latin America. <i>Pharmacogenomics</i> , 2016, 17, 1741-1747.	1.3	14
39	CYP450 genotype and pharmacogenetic association studies: a critical appraisal. <i>Pharmacogenomics</i> , 2016, 17, 259-275.	1.3	38
40	Interethnic variability of pharmacogenetic biomarkers in Mexican healthy volunteers: a report from the RIBEF (Ibero-American Network of Pharmacogenetics and Pharmacogenomics). <i>Drug Metabolism and Personalized Therapy</i> , 2016, 31, 61-81.	0.6	17
41	Multiplex Phenotyping for Systems Medicine: A One-Point Optimized Practical Sampling Strategy for Simultaneous Estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 Activities Using a Cocktail Approach. <i>OMICS A Journal of Integrative Biology</i> , 2016, 20, 88-96.	2.0	23
42	A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv121.	2.1	29
43	Pharmacogenetic Studies of Suicide: Potential Relevance of Main Polymorphic CYPs and ABCB1. , 2016, , 415-433.		0
44	Progress in pharmacogenetics: consortiums and new strategies. <i>Drug Metabolism and Personalized Therapy</i> , 2016, 31, 17-23.	0.6	12
45	Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population. <i>Revista De Biología Tropical</i> , 2016, 64, 1067-76.	0.4	10
46	Simultaneous Determination of Cytochrome P450 Oxidation Capacity in Humans: A Review on the Phenotyping Cocktail Approach. <i>Current Pharmaceutical Biotechnology</i> , 2016, 17, 1159-1180.	1.6	28
47	The Psychostimulant Khat (<i>Catha edulis</i>) Inhibits CYP2D6 Enzyme Activity in Humans. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 694-699.	1.4	25
48	Pharmacogenetics in Central American healthy volunteers: interethnic variability. <i>Drug Metabolism and Personalized Therapy</i> , 2015, 30, 19-31.	0.6	16
49	Population pharmacogenetics and global health. <i>Drug Metabolism and Personalized Therapy</i> , 2015, 30, 73-74.	0.6	7
50	Success stories in genomic medicine from resource-limited countries. <i>Human Genomics</i> , 2015, 9, 11.	2.9	41
51	Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1893-1905.	3.3	49
52	A Code of Ethics for Ethicists: What Would Pierre Bourdieu Say? "Do Not Misuse Social Capital in the Age of Consortia Ethics" <i>American Journal of Bioethics</i> , 2015, 15, 64-67.	0.9	14
53	Interethnic relationships of <i>CYP2D6</i> variants in native and Mestizo populations sharing the same ecosystem. <i>Pharmacogenomics</i> , 2015, 16, 703-712.	1.3	13
54	An Appeal to the Global Health Community for a Tripartite Innovation: An "Essential Diagnostics List," "Health in All Policies," and "See-Through 21 st Century Science and Ethics" <i>OMICS A Journal of Integrative Biology</i> , 2015, 19, 435-442.	2.0	14

#	ARTICLE	IF	CITATIONS
55	Metabolic phenotype prediction from genotyping data: a bottleneck for the implementation of pharmacogenetics in drug development and clinical practice. <i>Drug Metabolism and Personalized Therapy</i> , 2015, 30, 143-145.	0.6	4
56	A tribute to Jos� Mar�a ("Chema") Cant�. <i>Genetics and Molecular Biology</i> , 2014, 37, 310-314.	1.3	4
57	CYP2D6 Polymorphism and Mental and Personality Disorders in Suicide Attempters. <i>Journal of Personality Disorders</i> , 2014, 28, 873-883.	1.4	6
58	<i>CYP2D6</i> gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico. <i>Pharmacogenomics</i> , 2014, 15, 339-348.	1.3	28
59	First MEPS/HPLC assay for the simultaneous determination of venlafaxine and <i>O</i> -desmethylvenlafaxine in human plasma. <i>Bioanalysis</i> , 2014, 6, 3025-3038.	1.5	10
60	Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers. <i>Drug Metabolism and Drug Interactions</i> , 2014, 29, 129-141.	0.3	34
61	Research Highlights: Novel <i>CYP2C9</i> genetic polymorphisms and assessment of their impact on hydroxylation capacity. <i>Pharmacogenomics</i> , 2014, 15, 261-264.	1.3	1
62	<i>CYP2D6</i> genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas. <i>Pharmacogenomics</i> , 2014, 15, 1859-1865.	1.3	13
63	Interethnic variability of <i>CYP2D6</i> alleles and of predicted and measured metabolic phenotypes across world populations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1569-1583.	3.3	129
64	Ready to Put Metadata on the Post-2015 Development Agenda? Linking Data Publications to Responsible Innovation and Science Diplomacy. <i>OMICS A Journal of Integrative Biology</i> , 2014, 18, 1-9.	2.0	31
65	Bernard Lerer: Recipient of the 2014 Inaugural Werner Kalow Responsible Innovation Prize in Global Omics and Personalized Medicine (Pacific Rim Association for Clinical Pharmacogenetics). <i>OMICS A Journal of Integrative Biology</i> , 2014, 18, 211-221.	2.0	7
66	Present status and perspective of pharmacogenetics in Mexico. <i>Drug Metabolism and Drug Interactions</i> , 2014, 29, 37-45.	0.3	16
67	<i>CYP2D6</i> variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 673-683.	2.4	42
68	Translating Biotechnology to Knowledge-Based Innovation, Peace, and Development? Deploy a Science Peace Corps—An Open Letter to World Leaders. <i>OMICS A Journal of Integrative Biology</i> , 2014, 18, 415-420.	2.0	6
69	Liver enzyme abnormalities during antipsychotic treatment: a case report of risperidone-associated hepatotoxicity. <i>Drug Metabolism and Drug Interactions</i> , 2014, 29, 123-126.	0.3	9
70	Relationship between the <i>CYP2C9</i> IVS8-109A>T polymorphism and high losartan hydroxylation in healthy Ecuadorian volunteers. <i>Pharmacogenomics</i> , 2014, 15, 1417-1421.	1.3	15
71	Toward More Transparent and Reproducible Omics Studies Through a Common Metadata Checklist and Data Publications. <i>OMICS A Journal of Integrative Biology</i> , 2014, 18, 10-14.	2.0	54
72	A rapid and simple LC-MS/MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 hydroxylation capacity. <i>Bioanalysis</i> , 2014, 6, 683-696.	1.5	31

#	ARTICLE	IF	CITATIONS
73	Ethnic background and CYP2D6 genetic polymorphisms in Costa Ricans. <i>Revista De Biología Tropical</i> , 2014, 62, 1659.	0.4	15
74	Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations. <i>Molecular Biology Reports</i> , 2013, 40, 3187-3192.	2.3	18
75	Cytochrome P450 genetic polymorphisms of Mexican indigenous populations. <i>Drug Metabolism and Drug Interactions</i> , 2013, 28, 193-208.	0.3	15
76	Characterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: pharmacogenetic implications. <i>Personalized Medicine</i> , 2013, 10, 709-718.	1.5	11
77	Criterios de valoración clínicos y de funcionamiento en un estudio de interacción gen-ambiente en primeros episodios psicóticos (PEPs). <i>Revista De Psiquiatría Y Salud Mental</i> , 2013, 6, 4-16.	1.8	99
78	Impact of cytochrome P450 genes on suicide attempt and risk. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 703-704.	3.2	3
79	Pharmacogenetics of clinical response to risperidone. <i>Pharmacogenomics</i> , 2013, 14, 177-194.	1.3	36
80	Newly identified synergy between clopidogrel and calcium-channel blockers for blood pressure regulation possibly involves CYP2C19 rs4244285. <i>International Journal of Cardiology</i> , 2013, 168, 3057-3058.	1.7	2
81	CYP2D6 genetic polymorphism and psychiatry patients' hospitalization period. <i>Biomarkers in Medicine</i> , 2013, 7, 915-916.	1.4	5
82	Research Highlights. <i>Pharmacogenomics</i> , 2013, 14, 603-606.	1.3	0
83	MDR-1 genotypes and quetiapine pharmacokinetics in healthy volunteers. <i>Drug Metabolism and Drug Interactions</i> , 2013, 28, 163-166.	0.3	12
84	Clinical pharmacology of drug metabolism and drug interactions: clinical, interethnic and regulatory aspects. <i>Drug Metabolism and Drug Interactions</i> , 2013, 28, 1-3.	0.3	3
85	Evaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: the CEIBA cocktail. <i>Drug Metabolism and Drug Interactions</i> , 2013, 28, 135-146.	0.3	11
86	CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 627-630.	1.5	25
87	Toward More Transparent and Reproducible Omics Studies Through a Common Metadata Checklist and Data Publications. <i>Big Data</i> , 2013, 1, 196-201.	3.4	5
88	CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers. <i>Pharmacogenomics</i> , 2013, 14, 1973-1977.	1.3	23
89	Editorial: CPPM 2013 Onward: Building a Socio-Technical GPS for Global Personalized Medicine – A Welcome to Editors-In-Chief Adrian Llerena (Spain) and Ross A. McKinnon (Australia). <i>Current Pharmacogenomics and Personalized Medicine</i> , 2013, 11, 87-92.	0.2	0
90	CYP2D6 and the severity of suicide attempts. <i>Pharmacogenomics</i> , 2012, 13, 179-184.	1.3	37

#	ARTICLE	IF	CITATIONS
91	High-performance liquid chromatography method using ultraviolet detection for the quantification of aripiprazole and dehydroaripiprazole in psychiatric patients. <i>Drug Metabolism and Drug Interactions</i> , 2012, 27, 165-70.	0.3	2
92	Losartan hydroxylation phenotype in an Ecuadorian population: influence of <i>CYP2C9</i> genetic polymorphism, habits and gender. <i>Pharmacogenomics</i> , 2012, 13, 1711-1717.	1.3	28
93	Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. <i>Pharmacogenomics</i> , 2012, 13, 1773-1782.	1.3	17
94	Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of <i>CYP2C9</i> hydroxylation phenotypes. <i>Drug Metabolism and Drug Interactions</i> , 2012, 27, 217-223.	0.3	8
95	<i>CYP2D6</i> genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 637-644.	1.9	27
96	Eating Disorder Symptoms and <i>CYP2D6</i> Variation in Cuban Healthy Females: A Report from the Ibero-American Network of Pharmacogenetics. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2012, 10, 288-292.	0.2	4
97	Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine. <i>Drug Metabolism and Drug Interactions</i> , 2011, 26, 5-12.	0.3	22
98	ATA homozygosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: a case control study. <i>BMC Medical Genetics</i> , 2011, 12, 81.	2.1	15
99	Research Highlights. <i>Pharmacogenomics</i> , 2011, 12, 311-313.	1.3	2
100	Pharmacogenomics and Personality: Role of <i>CYP2D6</i> and Implications for Psychopathology. <i>Advances in Biological Psychiatry</i> , 2010, , 30-45.	0.2	3
101	Influence of <i>CYP2D6</i> Deletion, Multiplication, -1584C>G, 31G>A and 2988G>A Gene Polymorphisms on Dextromethorphan Metabolism among Mexican Tepehuanos and Mestizos. <i>Pharmacology</i> , 2010, 86, 30-36.	2.2	32
102	Evaluating a newly developed pharmacogenetic array: screening in a Spanish population. <i>Pharmacogenomics</i> , 2010, 11, 1619-1625.	1.3	12
103	Pharmacogenetics of debrisoquine and its use as a marker for <i>CYP2D6</i> hydroxylation capacity. <i>Pharmacogenomics</i> , 2009, 10, 17-28.	1.3	65
104	Development of a new genotyping assay for detection of the <i>BDNF</i> Val66Met polymorphism using melting-curve analysis. <i>Pharmacogenomics</i> , 2009, 10, 989-995.	1.3	6
105	Relation between <i>CYP2D6</i> genotype, personality, neurocognition and overall psychopathology in healthy volunteers. <i>Pharmacogenomics</i> , 2009, 10, 1111-1120.	1.3	49
106	<i>CYP2D6</i> genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies. <i>Pharmacogenomics</i> , 2009, 10, 685-699.	1.3	34
107	Relevance of <i>CYP2D6</i> -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients. <i>Pharmacogenomics</i> , 2009, 10, 1083-1089.	1.3	17
108	Increased use of second generation antipsychotic drugs in primary care: potential relevance for hospitalizations in schizophrenia patients. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 73-76.	1.9	16

#	ARTICLE	IF	CITATIONS
109	High risk of polydipsia and water intoxication in schizophrenia patients. <i>Schizophrenia Research</i> , 2008, 99, 377-378.	2.0	5
110	Subtyping undergraduate women along dietary restraint and negative affect. <i>Appetite</i> , 2008, 51, 727-730.	3.7	14
111	Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. <i>Pharmacogenomics</i> , 2008, 9, 833-840.	1.3	66
112	Aripiprazole-Induced Parkinsonism and Its Association With Dopamine and Serotonin Receptor Polymorphisms. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 352-353.	1.4	9
113	Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 9-19.	3.3	17
114	Association between T102C and A1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 835-8.	2.3	23
115	CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. <i>Pharmacogenomics</i> , 2007, 8, 1597-1608.	1.3	58
116	No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 527-528.	1.9	3
117	Editorial [Hot Topic: Pharmacogenetic and Pharmacogenomics (Guest Editors: A. Llerena and J. Licinio)]. <i>Current Drug Targets</i> , 2006, 7, 1639-1640.	2.1	0
118	Reduced completed suicide rate in Hungary from 1990 to 2001: Relation to suicide methods. <i>Journal of Affective Disorders</i> , 2005, 88, 235-238.	4.1	22
119	Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. <i>BioTechniques</i> , 2005, 39, S571-S574.	1.8	68
120	Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005, 43, 275-9.	2.3	13
121	Relationship between Haloperidol Plasma Concentration, Debrisoquine Metabolic Ratio, CYP2D6 and CYP2C9 Genotypes in Psychiatric Patients. <i>Pharmacopsychiatry</i> , 2004, 37, 69-73.	3.3	18
122	Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. <i>European Journal of Clinical Pharmacology</i> , 2004, 59, 869-873.	1.9	69
123	QTc Interval, CYP2D6 and CYP2C9 Genotypes and Risperidone Plasma Concentrations. <i>Journal of Psychopharmacology</i> , 2004, 18, 189-193.	4.0	69
124	Reproducibility over time of the urinary diclofenac/4-OH diclofenac ratio among different CYP2C9 genotypes. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2003, 28, 213-215.	1.6	2
125	Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 45-50.	1.9	46
126	CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 221-225.	1.9	95

#	ARTICLE	IF	CITATIONS
127	Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 783, 25-31.	2.3	52
128	Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 783, 213-219.	2.3	40
129	Analysis of diclofenac and its metabolites by high-performance liquid chromatography: relevance of CYP2C9 genotypes in diclofenac urinary metabolic ratios. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 789, 437-442.	2.3	20
130	Schizophrenia and tobacco smoking in a Spanish psychiatric hospital. <i>Schizophrenia Research</i> , 2003, 60, 313-317.	2.0	32
131	El estigma de la esquizofrenia entre estudiantes no graduados de medicina y enfermería. <i>European Psychiatry (Ed Española)</i> , 2003, 10, 132-133.	0.0	0
132	QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. <i>Journal of Psychopharmacology</i> , 2002, 16, 361-364.	4.0	58
133	Schizophrenia and tobacco smoking in a Spanish psychiatric hospital. <i>Schizophrenia Research</i> , 2002, 58, 323-327.	2.0	13
134	Schizophrenia stigma among medical and nursing undergraduates. <i>European Psychiatry</i> , 2002, 17, 298-299.	0.2	43
135	QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 223-224.	1.9	18
136	Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 89-98.	4.7	164
137	The Underlying Traits of the Karolinska Scales of Personality (KSP). <i>European Journal of Psychological Assessment</i> , 2002, 18, 139-148.	3.0	42
138	Effect of Thioridazine Dosage on the Debrisoquine Hydroxylation Phenotype in Psychiatric Patients With Different CYP2D6 Genotypes. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 616-620.	2.0	48
139	Determination of clozapine and its N-desmethyl metabolite by high-performance liquid chromatography with ultraviolet detection. <i>Biomedical Applications</i> , 2001, 755, 349-354.	1.7	18
140	Clozapine Withdrawal Symptoms after Change to Sertindole in a Schizophrenic Patient. <i>Pharmacopsychiatry</i> , 2000, 33, 42-44.	3.3	10
141	Use of the Mesoridazine/Thioridazine Ratio as a Marker for CYP2D6 Enzyme Activity. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 397-401.	2.0	38
142	Pharmacokinetic Interaction of Fluvoxamine and Thioridazine in Schizophrenic Patients. <i>Journal of Clinical Psychopharmacology</i> , 1999, 19, 494-499.	1.4	58
143	Influence of genetic admixture on polymorphisms of drug-metabolizing enzymes: Analyses of mutations on NAT2 and CYP2E1 genes in a mixed Hispanic population*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 623-628.	4.7	27
144	Molecular heterogeneity at the CYP2D gene locus in Nicaraguans: impact of gene-flow from Europe. <i>Pharmacogenetics and Genomics</i> , 1997, 7, 337-340.	5.7	23

#	ARTICLE	IF	CITATIONS
145	A PVC-graphite composite electrode for electroanalytical use. Preparation and some applications. <i>Analytica Chimica Acta</i> , 1997, 355, 23-32.	5.4	53
146	Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.. <i>British Journal of Clinical Pharmacology</i> , 1995, 40, 467-476.	2.4	53
147	Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms.. <i>British Journal of Clinical Pharmacology</i> , 1994, 37, 71-74.	2.4	87
148	Fixed combinations of neuroleptics with antidepressants: potential risks and estimation of use.. <i>British Journal of Clinical Pharmacology</i> , 1994, 37, 531-532.	2.4	5
149	Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.. <i>British Journal of Clinical Pharmacology</i> , 1994, 38, 471-473.	2.4	245
150	Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 54, 606-611.	4.7	58
151	Reproducibility over Time of Mephenytoin and Debrisoquine Hydroxylation Phenotypes. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1993, 73, 46-48.	0.0	5
152	Relationship between personality and debrisoquine hydroxylation capacity. <i>Acta Psychiatrica Scandinavica</i> , 1993, 87, 23-28.	4.5	152
153	GENETIC FACTORS IN THE METABOLISM OF HALOPERIDOL.. <i>Clinical Neuropharmacology</i> , 1992, 15, 84A-85A.	0.7	2
154	Haloperidol Disposition Is Dependent on the Debrisoquine Hydroxylation Phenotype. <i>Therapeutic Drug Monitoring</i> , 1992, 14, 261-264.	2.0	99
155	Haloperidol Disposition Is Dependent on Debrisoquine Hydroxylation Phenotype. <i>Therapeutic Drug Monitoring</i> , 1992, 14, 92-97.	2.0	174
156	Polymorphic oxidation of debrisoquine in lung cancer patients. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 158-161.	0.7	20
157	Polymorphic Oxidation of Debrisoquine in Women with Breast Cancer. <i>Oncology</i> , 1991, 48, 107-110.	1.9	21
158	Polymorphic Oxidation of Debrisoquine in Bladder Cancer. <i>Annals of Medicine</i> , 1990, 22, 157-160.	3.8	13
159	Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 45, 328-333.	4.7	46
160	Debrisoquin oxidation polymorphism in a Spanish population. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 44, 74-76.	4.7	54
161	CYP2D6 Polymorphism and Mental and Personality Disorders in Suicide Attempters. <i>Journal of Personality Disorders</i> , 0, , 1-11.	1.4	4